活血化瘀消癥通络中药治疗糖尿病肾病76例临床研究

Treating 76 cases of diabetic nephropathy by the Huoxue Huayu Xiaozheng Tongluo medicine

目的:观察活血化瘀消癥通络中药对糖尿病肾病(DN)的临床疗效。方法:将76例DN患者随机分为治疗组和对照组,治疗组39例,对照组37例。两组均接受常规降血糖治疗。治疗组口服活血化瘀消癥通络胶囊,口服4粒/次,每日3次,对照组口服苯那普利,口服10mg/次,每日1次。治疗12个月,测定尿微量白蛋白尿排泄率(UAER),血β2-微球蛋白(β2-MG)、尿β2-MG、尿α1-微球蛋白(α1-MG)、D-二聚体(D-D)、血浆纤维蛋白原(FIB)。结果:治疗前两组患者的UAER、血β2-MG、尿β2-MG、尿α1-MG、FIB、D-D水平差异无统计学意义(P> 0.05)。治疗后FIB、D-D水平与治疗前比较,有显着性差异,具有统计学意义(P <0.05)。结论:活血化瘀消癥通络中药治疗DN,在降低尿蛋白、改善肾功能和高凝状态方面明显优于苯那普利。

Objective： To observe the clinical efect of the Huoxue Huayu Xiaozheng Tongluo （ 活血化瘀消癥通络 ） medicine on DN. Methods： 76 patients were randomly divided into the treatment group （39 cases） and control group （37 cases）. Two groups received routine hypoglycemic therapy. The treatment group was given the Huoxue Huayu Xiaozheng Tongluo capsule. The control group was given Benazepril. After 12 months, UAER, serum β2-MG, urinary β2-MG, urinary α1-MG, D-D, and FIB were measured. Results： There was no signifcant diference in UAER, serum β2-MG, urinary β2-MG, urinary α1-MG, FIB and D-D between groups before treatment （P〉0.05）.The levels of FIB and D-D after treatment were signifcantly diferent from those before treatment （P〈0.05）. Conclusion： The Huoxue Huayu Xiaozheng Tongluo medicine is superior to Benazepril in reducing urinary protein, improving renal function and hypercoagulable state.